Efficacy and safety of the proposed biosimilar PERT-IJS versus EU-Perjeta® along with trastuzumab and chemotherapy (carboplatin and docetaxel) as neoadjuvant treatment in chemotherapy naïve patients with early stage or locally advanced HR negative and HER2 positive breast cancer

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506163-34-00

Acronym

BIO-PERTUZ-301

Enrollment

Registered

2023-11-22

Start date

Unknown

Completion date

2025-02-24

Last updated

2023-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hormone Receptor Negative (HR-ve) Human Epidermal Growth Factor Receptor 2 (HER2)-positive Early Stage or Locally Advanced Breast Cancer

None listed

Sex/Gender

All

Age

18 Years to No maximum

Poland, Romania

None listed

Source: EU CTIS · Data processed: Feb 4, 2026